Balanced news tone
News Sentiment
KROS sentiment intelligence
Keros Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
49
Balanced news tone
48 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+4.9% over one week, -4.8% over four weeks, trend inactive, and below fair value.
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
4.9%
Price confirming higher
Trend fit
Trend inactive
-4.8% over four weeks
Fair value
-65.4%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
23
Negative
14
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Moomoo
Direct company coverage
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16
Wedbush has reiterated its Hold rating on Keros Therapeutics (KROS.US) and maintained its target price at $16. This report indicates a continued neutral stance on the company's stock by the analyst firm.
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 20 May 2026 06:09
- Source
- Moomoo
Stock Titan
Direct company coverage
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan
A director at Keros Therapeutics, Jean Jacques Bienaime, purchased 1,000 shares of common stock in an open-market transaction on May 15, 2026, at a weighted average price of $10.58 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on D
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 19 May 2026 20:09
- Source
- Stock Titan
Market source
Direct company coverage
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 17 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 04 Mar 2026 08:00
- Source
- Market source
TradingView
Direct company coverage
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 Jan 2026 08:00
- Source
- TradingView
Trefis
Direct company coverage
Is Keros Therapeutics Stock Built to Withstand More Downside?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 21 Dec 2025 08:00
- Source
- Trefis
simplywall.st
Industry context
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Dec 2025 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Nov 2025 08:00
- Source
- simplywall.st
Reuters
Direct company coverage
Keros shares plunge as safety doubts prompt dosing pause in blood pressure drug trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2024 08:00
- Source
- Reuters
MarketBeat
Direct company coverage
Keros Therapeutics (KROS) Stock Price, News & Analysis $KROS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2020 02:18
- Source
- MarketBeat